Development Pipeline

Targeted Therapeutics Pipeline

Our targeted oral delivery platform uses a smart capsule designed for targeted delivery of therapeutics to the large intestine to achieve sufficient tissue concentration. Delivering therapeutics directly to the site of disease could enable safer and more effective treatment of inflammatory bowel disease (IBD).

Learn More
Program Indication Design / Feasibility Preclinical Clinical

DDS
Targeted Oral Delivery Platform

Clinical

BT-600
DDS + tofacitinib

Ulcerative Colitis
Preclinical

BT-001
DDS + adalimumab variant

Ulcerative Colitis
Preclinical

Systemic Therapeutics Pipeline

Our systemic oral delivery platform uses an ingestible capsule designed for liquid jet delivery of biotherapeutics into the small intestine for systemic uptake. Needle-free delivery could replace injection for better management of chronic diseases.

Learn More
Program Indication Design / Feasibility Preclinical Clinical

OBDS
Systemic Oral Delivery Platform

Preclinical

BT-200
OBDS + GLP-1 receptor agonist

Diabetes
Preclinical

BT-002
OBDS + adalimumab variant

Autoimmune
Preclinical

Ionis Collaboration
OBDS + antisense therapy

Undisclosed
Design/Feasibility

Large Pharma 1 Collaboration
OBDS + undisclosed drug

Undisclosed
Design/Feasibility

Large Pharma 2 Collaboration
OBDS + undisclosed drug

Undisclosed
Design/Feasibility